Aron Flagg

Aron Flagg

Auto-generated profile, based on publicly available information

Aron Flagg

Department of Pediatric Hematology & Oncology, Yale School of Medicine, New Haven, CT. USA

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 January 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
APAndrew R. Patterson
Andrew R. Patterson
MEMehari Endale
Mehari Endale
KLKristin Lampe
Kristin Lampe
HAHalil I. Aksoylar
Halil I. Aksoylar
AFAron Flagg
Aron Flagg
KHKasper Hoebe
Kasper Hoebe
GTPase of immunity-associated protein 5 (Gimap5) is linked with lymphocyte survival, autoimmunity, and colitis, but its mechanisms of action are unclear. Here, we show that Gimap5 is essential for the inactivation of glycogen synthase kinase-3β (GSK3β) following T cell activation. In the absence of Gimap5, constitutive GSK3β activity constrains c-Myc induction and NFATc1 nuclear import, thereby limiting productive CD4+T cell proliferation. Additionally, Gimap5 facilitates Ser389 phosphorylation and nuclear translocation of GSK3β, thereby limiting DNA damage in CD4+T cells. Importantly, pharmacological inhibition and genetic targeting of GSK3β can override Gimap5 deficiency in CD4+T cells and ameliorates immunopathology in mice. Finally, we show that a human patient with aGIMAP5loss-of-function mutation has lymphopenia and impaired T cell proliferation in vitro that can be rescued with GSK3 inhibitors. Given that the expression of Gimap5 is lymphocyte-restricted, we propose that its control of GSK3β is an important checkpoint in lymphocyte proliferation.

1 January 2004 in Resuscitation
Verified
Journal Article
Closed access
LSLawrence D. Sherman
Lawrence D. Sherman
AFAron Flagg
Aron Flagg
CCClifton W. Callaway
Clifton W. Callaway
JMJames J. Menegazzi
James J. Menegazzi
MHMargaret Hsieh
Margaret Hsieh

11 April 2024 in Blood Advances
Verified
Journal Article
Open access
PDF file
LKLakshmanan Krishnamurti
Lakshmanan Krishnamurti
JLJingchen Liang
Jingchen Liang
ZHZili He
Zili He
YDYanghong Deng
Yanghong Deng
VNVineetha R. Nallagatla
Vineetha R. Nallagatla
NSNiketa Shah
Niketa Shah
Vaso-occlusive episodes (VOC) or pain crises are the most common indications for hematopoietic cell transplantation (HCT) for sickle cell disease (SCD). Elimination of pain crisis after HCT is an important patient-centered outcome and may improve understanding of the natural history of pain syndromes in SCD. We examined deidentified records of 763 patients followed-up for a median of 36.7 months (range, 0.3-168.6 months), with 69.6% patient's age 10 years at HCT (range, 11-17 years; OR, 9.43; 95% CI, 3.20-27.79; P < .0001), in age ≥18 years (OR, 16.62; 95% CI, 5.85-47.16; P < .0001), in those with history of pain crisis 2 years before HCT (OR, 13.16; 95% CI, 4.08-42.42; P < .0001), alternate donors (haploidentical [OR, 4.80; 95% CI, 2.48-9.31; P < .0001], unrelated matched [OR, 2.71; 95% CI, 1.23-5.97; P = .0132], and mismatched unrelated [OR, 3.19; 95% CI, 1.44-7.05; P = .0041], and those with GF (n = 41 [5.37%]; OR, 7.15; 95% CI, 4.20-12.18; P < .0001). Pain crisis was less frequent with KPS of ≥90 (OR, 0.31; 95% CI, 0.18-0.55; P < .0001). Multivariable logistic regression models confirmed age at HCT, KPS, graft type, donor type, history of VOC 2 years before HCT, and GF as independent predictors of pain crisis after HCT and generated predictive models and nomograms for pain crisis after HCT for SCD, which can support shared decision making.

21 April 2022 in Blood Advances
Verified
Journal Article
Open access
PDF file
UMUpendra Mahat
Upendra Mahat
BGBhavuk Garg
Bhavuk Garg
Chao-Yie YangChao-Yie Yang
Chao-Yie Yang
HMHrishikesh Mehta
Hrishikesh Mehta
RHRabi Hanna
Rabi Hanna
SCSeth J. Corey
Seth J. Corey
Neutrophils migrate into inflamed tissue, engage in phagocytosis, and clear pathogens or apoptotic cells. These processes require well-coordinated events involving the actin cytoskeleton. We describe a child with severe neutropenia and episodes of soft tissue infections and pneumonia. Bone marrow examination showed granulocytic hypoplasia with dysplasia. Whole-exome sequencing revealed a de novo heterozygous missense mutation in LCP1, which encodes the F-actin–binding protein Lymphocyte Cytosolic Protein 1. To determine its pathophysiological significance, we stably transduced cells with doxycycline-inducible wild-type LCP1 and LCP1 I232F lentiviral constructs. We observed dysplastic granulocytic 32D cells expressing LCP1 I232F cells. These cells showed decreased proliferation without a block in differentiation. In addition, expression of LCP1 I232F resulted in a cell cycle arrest at the G2/M phase, but it did not lead to increased levels of genes involved in apoptosis or the unfolded protein response. Both 32D and HeLa cells expressing mutant LCP1 displayed impaired cell motility and invasiveness. Flow cytometry showed increased F-actin. However, mutant LCP1-expressing 32D cells exhibited normal oxidative burst upon stimulation. Confocal imaging and subcellular fractionation revealed diffuse intracellular localization of LCP1, but only the mutant form was found in the nucleus. We conclude that LCP1 is a new gene involved in granulopoiesis, and the missense variant LCP1 I232F leads to neutropenia and granulocytic dysplasia with aberrant actin dynamics. Our work supports a model of neutropenia due to aberrant actin regulation.

1 July 2018 in Reumatología Clínica
Verified
Journal Article
Closed access
PCPaz Collado
Paz Collado
AKAml Kelada
Aml Kelada
MCMaria Cámara
Maria Cámara
AZAndrew Zeft
Andrew Zeft
AFAron Flagg
Aron Flagg

6 March 2017 in Transplant Infectious Disease
Verified
Journal Article
Closed access
PDF file
RCRitika Coelho
Ritika Coelho
RHRabi Hanna
Rabi Hanna
AFAron Flagg
Aron Flagg
LSLisa M. Stempak
Lisa M. Stempak
SOSarah Ondrejka
Sarah Ondrejka
BGBlanca E. Gonzalez
Blanca E. Gonzalez